Literature DB >> 12118185

Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size.

Nicole S Wayman1, Belinda L Ellis, Christoph Thiemermann.   

Abstract

BACKGROUND: This study was designed to investigate the effects of two, chemically distinct activators of PPAR-a (clofibrate and WY14643) in a rat model of acute myocardial infarction. MATERIAL/
METHODS: Male Wistar rats were anesthetized with sodium thiopentone (120 mg/kg i.v.) and subjected to regional myocardial ischemia (for 25 min) and reperfusion (for 2 h). Area at risk was determined by injection of Evans Blue dye and infarct size after staining with nitroblue tetrazolium.
RESULTS: Pre-treatment of rats with the PPAR-a agonists clofibrate (0.3 mg/kg) caused a significant reduction in myocardial infarct size of 43%. Similarly, pre-treatment of rats with the PPAR-a agonists WY14643 (1 mg/kg) caused a significant reduction in myocardial infarct size of 43%.
CONCLUSIONS: Taken together, these results show that ligands of PPAR-a reduce the tissue necrosis associated with acute myocardial infarction. We propose that fibrates and other PPAR-a agonists may be useful in conditions associated with ischemia-reperfusion of the heart and other organs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118185

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  6 in total

1.  Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta.

Authors:  Pascal J H Smeets; Birgit E J Teunissen; Anna Planavila; Heleen de Vogel-van den Bosch; Peter H M Willemsen; Ger J van der Vusse; Marc van Bilsen
Journal:  J Biol Chem       Date:  2008-08-12       Impact factor: 5.157

Review 2.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

Review 3.  PPARs: Protectors or Opponents of Myocardial Function?

Authors:  Christine J Pol; Melissa Lieu; Konstantinos Drosatos
Journal:  PPAR Res       Date:  2015-12-02       Impact factor: 4.964

4.  Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Authors:  Alexander Tenenbaum; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2004-12-01       Impact factor: 9.951

5.  The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium.

Authors:  Jennifer G Duncan; Brian N Finck
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

6.  Involvement of Inflammatory Cytokines in Antiarrhythmic Effects of Clofibrate in Ouabain-Induced Arrhythmia in Isolated Rat Atria.

Authors:  Somayeh Moradi; Vahid Nikoui; Muhammad Imran Khan; Shayan Amiri; Farahnaz Jazaeri; Azam Bakhtiarian
Journal:  Adv Pharmacol Sci       Date:  2016-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.